Abstract Tardive dyskinesia (TD) is a debilitating, unpredictable, and often irreversible side effect resulting from chronic treatment with typical antipsychotic agents such as haloperidol. TD is characterized by repetitive, involuntary, purposeless movements primarily of the orofacial region. In order to investigate genetic susceptibility to TD, we used a validated mouse model for a systems genetics analysis geared toward detecting genetic predictors of TD in human patients. Phenotypic data from 27 inbred strains chronically treated with haloperidol and phenotyped for vacuous chewing movements were subject to a comprehensive genomic analysis involving 426,493 SNPs, 4,047 CNVs, brain gene expression, along with gene network and bioinformatic analysis. Our results identified *50 genes that we expect to have high prior probabilities for association with haloperidol-induced TD, most of which have never been tested for association with human TD. Among our top candidates were genes regulating the development of brain motor control regions (Zic4 and Nkx6-1), glutamate receptors (Grin1 and Grin2a), and an indirect target of haloperidol (Drd1a) that has not been studied as well as the direct target, Drd2.
Introduction
First-generation or ''typical'' antipsychotics (prototype haloperidol) can cause a number of motor side effects that are collectively termed extrapyramidal syndromes (EPS) (Dayalu and Chou 2008; Hsin-tung and Simpson 2000) . Of all patients who initiate treatment, *40% experience restlessness, involuntary spasms, or muscular rigidity in the first few weeks and these symptoms are alleviated to varying degrees by anticholinergic agents (Simpson 1970) . Of all patients who sustain long-term treatment ([3 months), *35% develop the EPS tardive dyskinesia (TD) (Dayalu and Chou 2008; Hsin-tung and Simpson 2000) . TD is characterized by repetitive, involuntary, and purposeless movements, primarily of the orofacial region (e.g., chewing movements and tongue protrusion) (Crane 1968) . Of all individuals who develop TD, it is irreversible in *50% of cases (Soares-Weiser and Fernandez 2007 and there is currently no validated and widely accepted treatment for it (Tandon et al. 2008) . Therefore, the physician cannot predict whether a patient will develop TD and, without efficacious treatments, a large number of patients are left with a disfiguring condition.
While familial occurrence of TD has been observed in a few small studies (Muller et al. 2001; O'Callaghan et al. 1990; Yassa and Ananth 1981) , there are no heritability estimates for susceptibility to TD in humans. Despite lack of known heritability, a number of candidate genes have been tested for associations with TD. The results are generally inconsistent. The most encouraging data are for DRD3, HTR2A, HTR2C, and CYP2D6, with positive meta-analyses for each (Bakker et al. 2006; Lerer et al. 2005; Patsopoulos et al. 2005; Reynolds et al. 2005) . Negative results have been obtained for DRD2, DRD4, COMT, MAOA, MAOB, and enzymes related to oxidative stress (Herken et al. 2003; Kaiser et al. 2002; Lai et al. 2005; Lee et al. 2007; Matsumoto et al. 2004) . Many of these studies suffered from the limitations of examining just one gene at a time, and usually only a single genetic variant, and suboptimal power due to small sample sizes (n \ 500). We have completed a genome-wide association study (GWAS) of TD by analyzing 492,900 single nucleotide polymorphisms (SNPs) in 214 TD cases and 524 controls with schizophrenia, and no association exceeded chance expectations (Aberg et al. 2010) .
Because of limited progress with human pharmacogenomic studies, we explored the potential of a complementary mouse-then-human experimental paradigm (Harrill et al. 2009; Rusyn et al. 2010 ). We exposed diverse inbred mouse strains to human-like steady-state drug concentrations and measured outcomes of relevance to TD. All strains were previously genotyped using a dense SNP chip (Yang et al. 2009 allowing genetic mapping in silico. Human orthologs of genomic regions strongly implicated in mouse can then be used to reduce the genetic search space in humans to determine whether the association replicates across species.
After chronic treatment with typical antipsychotics, rodents show purposeless mouth openings in the vertical plane (vacuous chewing movements, VCMs) (Waddington et al. 1983 ). VCMs are a phenotypically and pharmacologically valid animal model of TD that has been used for decades by behavioral pharmacologists (Turrone et al. 2002 (Turrone et al. , 2003 . A large body of research has shown that haloperidolinduced VCM closely mimics nearly every characteristic of human TD (Soares-Weiser and Fernandez 2007) . In a recent study from our laboratory (Crowley et al. 2010 ), we exposed 27 genetically inbred mouse strains to standardized doses of haloperidol for 120 days in order to calculate heritability and to identify optimal phenotypes for genetic association mapping. This study yielded five critical pieces of information. First, we showed that it is possible to deliver human-like steady-state concentrations of haloperidol to diverse mouse strains in a reliable manner with implantable drug pellets. Second, we demonstrated that haloperidol plasma concentrations are highly variable between inbred strains with heritability estimates of *0.7 and are not influenced by potential confounders such as the dose implanted or body mass. Third, we observed marked behavioral changes across multiple domains. Four measures of activity in the open field, rigidity on an inclined screen (a measure of EPS), and four measures of orofacial movement all exhibited, on average, marked changes following haloperidol exposure. Crucially, these measures were independent of haloperidol plasma level and strain was again the major predictor of phenotypic variation. Fourth, we observed that the behavioral domains we assessed were not discrete constructs but rather loaded onto two factors (Supplementary Table 1 ). One factor loaded primarily on antipsychoticinduced changes in open field activity (''OFA''), while the other loaded primarily on haloperidol-induced orofacial movements (''Orofacial''). Finally, we found high heritabilities for haloperidol-induced effects on VCMs, activity in the open field, and EPS. Heritabilities for each of these phenotypes exceeded 75%, and heritability of the factors OFA and Orofacial were *0.9, after incorporation of the longitudinal nature of the design (Crowley et al. 2010 ).
In the current study, we perform genetic association mapping of the highly heritable factors OFA and Orofacial from Crowley et al. (2010) , haloperidol levels, and a composite measure of EPS. A comprehensive genomic analysis approach was taken, including tests of association with genome-wide SNPs, biological pathways, copy number variants (CNVs), and gene expression from the brains of the animals tested.
Materials and methods

Phenotypic data
The collection of the phenotypic data for this study is described in detail in Crowley et al. (2010) . For GWAS mapping, we chose four phenotypes from Crowley et al.: (1) a principal component loading primarily on antipsychotic-induced changes in open field activity (OFA), (2) a principal component loading primarily on antipsychoticinduced changes in orofacial movements (Orofacial), (3) the log 10 transformation of plasma haloperidol levels 30 days after drug pellet implantation (HAL30), and (4) a basic linear unbiased predictor of changes in inclined screen rigidity across 120 days of drug treatment (EPS), a commonly used measure of extrapyramidal symptoms in the literature (Chipkin et al. 1988) .
Animals
All testing procedures were conducted in strict compliance with the Guide for the Care and Use of Laboratory Animals and approved by the Institutional Animal Care and Use Committee of the University of North Carolina. Male mice (aged 8-10 weeks at the start of testing) from 27 inbred strains (N = 5-9 mice/strain) were obtained from the Jackson Laboratory (Bar Harbor, ME) through the Mouse Phenome Project (Bogue and Grubb 2004) . A total of 22 classical and 5 wild-derived strains were examined (Supplementary Table 2 ). Animals were maintained on a 12-h light:12-h dark schedule, with lights on at 0700. The housing room was maintained at 20-24°C with 40-50% relative humidity. Mice were housed in standard 20 9 30-cm ventilated polycarbonate cages with laboratory grade Bed-O-Cob bedding. Water and Purina ProLab IsoPro 3,000 were available ad libitum. All mice were grouphoused (maximum of 5 per cage) except that BALB/cByJ, CAST/EiJ, and SJL/J mice were separated due to fighting after 7, 10, and 13 weeks of housing, respectively. All phenotypes were measured on days 0, 30, 60, 90, and 120 relative to drug treatment (day 1).
Antipsychotic exposure
Slow-release haloperidol pellets (3.0 mg/kg/day; Innovative Research of America, Sarasota, FL) (Fleischmann et al. 2002) designed for 60 days of continuous release were implanted subcutaneously with a trocar under 2 min of isoflurane anesthesia. Blood plasma was collected via tail nick for drug concentration assays after 30, 60, 90, and 120 days of exposure to haloperidol. Human-like steady-state concentrations of haloperidol (3.75-19 ng/ml) (Hsin-Tung and Simpson 2000) were achieved in 98% of mice. Supplementary Fig. 1 shows haloperidol plasma levels for each strain across the duration of this study.
Scoring VCMs
High-resolution digital videotapes of orofacial behavior were made by modifying the method of Tomiyama et al. (2001) (Supplementary Fig. 2 ). Each mouse was placed in a restrictor device for 25 min, and the final 15 min were scored for orofacial movement phenotypes: tongue protrusions, overt chewing movements, subtle chewing movements, and jaw tremors.
Open field activity
Extrapyramidal side effects may appear as general motor deficits in mice. Therefore, spontaneous locomotor activity in the open field (Crawley 1985) was measured for 1 h using an automated apparatus (Accuscan Instruments, Columbus, OH). Four phenotypes were extracted from these activity data: total distance traveled (cm), vertical activity, stereotypy, and time spent in the central region of the chamber (percent of total time; central region = 20 9 20 cm).
Extrapyramidal side effects (EPS)
The inclined screen test (Barnes et al. 1990 ) was used as an index of Parkinsonian rigidity and sedation. Mice were placed on a wire mesh screen inclined at 45°and the latency to move all four paws was recorded (maximum of 300 s).
Phenotypic statistical analysis
Linear mixed-effects models (Crowley et al. 2010 ) were used to decompose phenotype variances for the calculation of heritability and to assess the significance of covariate fixed effects (R 2.6.0 and Stata 9.2). Heritability was calculated using intraclass correlation coefficients. The heritabilities of the over-time trajectories in haloperidolinduced movement disorder phenotypes were assessed using an extension of the mixed model for behavioral genetic analysis (Goldstein 1995) . We applied factor analysis to examine the factor structure of the mousespecific response trajectories (MPlus 5.21) (Joreskog 1969; Muthén and Muthén 2003; Van Prooijen and Van Der Kloot 2001) , and individual response phenotype trajectories were decomposed into strain-and mouse-level components, with heritabilities calculated as the ratio of strainlevel variance to strain-level ? mouse-level variance ( Supplementary Fig. 3 ).
SNP genotypes
All 27 strains were genotyped at the Jackson Laboratory using the Affymetrix Mouse Diversity Array (Yang et al. 2009 ) which contains 623,124 SNPs. Prior to association mapping, we removed singletons, heterozygous or missing genotypes, and highly variable probes suggestive of variation within the probe sequence (Yang et al. 2009 ). A total of 426,493 SNPs remained for association analysis following quality control.
Association mapping
Due to the population substructure among commercially available inbred strains, it is critically important to avoid false associations owing to population stratification. Therefore, a three-step process was used for genome-wide association mapping in an effort to reduce the effect of population stratification and increase confidence in mapped loci. First, we used EMMA (Efficient Mixed Model Association) (Kang et al. 2008 ) to assess evidence of association between each SNP and phenotype. EMMA implements a linear mixed model to account for population structure and genetic relatedness among strains by estimating the pairwise relatedness between all individuals and fitting these to the phenotype vector. We controlled Type I multiple testing error using permutation by shuffling the strain label while keeping the genotype vectors intact (1,000 permutations). The percentiles of the minimum P value per permutation were used to determine genomewide significance thresholds adjusting for multiple testing. Thresholds were 3.4E -8, 1.6E -6, 8.7E -13, and 9.5E -6 for OFA, Orofacial, EPS, and HAL30, respectively. As a check, EMMA was applied after removing the five wild-derived strains because population stratification artifacts are more likely with these genetically divergent strains (Kang et al. 2008) . Second, we used TreeQA (Pan et al. 2009 ) to examine the reproducibility of EMMA results. TreeQA is a quantitative genome-wide association mapping algorithm that uses local phylogenies constructed in genomic regions exhibiting no evidence of historical recombination. Finally, to confirm the robustness of allelic effects, we performed a univariate test (Wilcoxon rankedsum) using single SNP genotypes as predictors of the primary phenotypic values.
Pathway analysis
We used Ingenuity Pathway Analysis (v6.0) which contains curated biological interactions and functional annotation. As input, we selected the top 1% of genes in each phenotype ranked by minimum P value. The P value cutoffs for the top 1% genes were 0.00057, 0.000274, 8.04E -7, and 0.000321 for OFA, Orofacial, EPS, and HAL30.
Bioinformatic analysis
First, we selected all SNPs with EMMA P B 0.0001. Second, we annotated each SNP using UCSC's KnownGene Hsu et al. 2006) , mouse QTL data (Blake et al. 2011 ), OMIM (McKusick 2007 , The Jackson Laboratory's Mouse Phenotype Database (Blake et al. 2011) , and The Sanger Institute Mouse SNPs database (www.sanger.ac.uk/resources/mouse/genomes). We extracted information from the first three databases when the position of each SNP maps within the interval of start and end positions of each entry. For the QTL database, we chose a window of ±5 Mb, since QTL in standard crosses are not mapped to high resolution. The Sanger SNPs database has full-genome sequence for 13 of the 27 strains we studied.
CNV analysis
The same Mouse Diversity Array. CEL files that were used to genotype SNPs were used for CNV calling. We analyzed hybridization intensity data from 622,995 SNPs and 597,225 exon probe sets using PennCNV (Wang et al. 2007 ) to generate an initial set of CNV calls. We then applied a multistep quality control procedure (remove CNVs that overlap array gaps, remove small, low-confidence, or sparse CNVs) to derive at the most confident call set (a total of 4,047 CNV regions were predicted across 26 strains). We do not currently know the level of false-negative and false-positive CNV calls in this data set but are currently using an independent methodology to examine the validity of these calls. This CNV data set will be the focus of a future publication. We used binary CNV genotypes for genome-wide association with EMMA. Finally, we checked for the presence of CNVs in regions with EMMA SNPs with P \ 0.0001 for each phenotype.
Gene expression analysis
The animals used for gene expression are the same ones described in detail in Crowley et al. (2010) , in which each animal was treated with haloperidol for 120 days and behaviorally phenotyped. At the completion of drug treatment, whole brain was collected from 92 animals (25 strains, average of 4 brains/strain, Supplementary Table 3) and total RNA was extracted using an automated Maxwell 16 Instrument (Promega, Madison, WI). All samples were processed according to the manufacturer's instructions and hybridized to an Affymetrix Mouse Gene 1.1 ST 96-Array Plate (Affymetrix, Santa Clara, CA). Before analysis, we removed probes containing a known genetic variant from Sanger Institute resequencing. We used the RMA method for background adjustment, quantile normalization, and to estimate target and probe effects. Using the probe-set summarized data, we ran a simple linear regression model to test whether changes of expression levels were associated with phenotype. For pathway analysis, we used SAFE (Barry et al. 2005 ), a two-stage, permutation-based method that accounts for the unknown correlation among genes. Finally, we calculated association between SNP genotype and gene expression levels for EMMA SNPs with P \ 0.0001. We collected all probe sets within 1 Mb of these SNPs, stratified gene expression values by SNP genotype, and tested for a significant expression difference between the two genotypes using t test. For each phenotype, we calculated adjusted P values using false discovery rate.
Results
Phenotypic data
We first selected four phenotypes from Crowley et al. (2010) with optimal properties for genetic analysis. To this end, we chose one trait with high heritability (all [0.8) for four domains of primary interest: VCMs (Orofacial), pharmacokinetics (HAL30), rigidity (EPS), and open field activity (OFA). Figure 1 shows the 27-strain distribution for each of these phenotypes. First, the five wild-derived strains (CAST, PWK, WSB, MSM, and MOLF) were evenly distributed among Orofacial and HAL30 but tended to be less affected by haloperidol in the inclined screen and open field activity tests. Since this could cause spurious GWAS results owing to population stratification, we decided to run GWA for all traits with and without wild-derived strains. Second, strains derived from New Zealand (NZL, NZO, and NZW) were susceptible to haloperidol-induced rigidity on the inclined screen test (Fig. 1c) and had higher levels of haloperidol (Fig. 1b) . For EPS we still found an overabundance of GWAS peaks with P \ 1 9 10 -5 , suggesting residual stratification effects. To test this, we ran EMMA with the three New Zealand strains removed and found the top peak to be just 3.1 9 10 -5 ( Supplementary Fig. 4 ), confirming our suspicion. However, since we believe that the high EPS susceptibility of the New Zealand strains is a true genetic effect, we decided to leave them in the analysis, calculate a permutation-based genome-wide significance level for each phenotype (see below), and focus follow-up analyses on the top 1% of SNP-associated loci. Finally, we found a great deal of variability among the eight Collaborative Cross (Churchill ). This association was robust to analytical method (Table 1 ). This region contains 12 known genes and 6 predicted genes, several of which are expressed in brain (e.g., Cpeb2 and Bst1). A search of the literature did not reveal any immediate links between genes in this locus and haloperidol pharmacology, movement disorders, or monoamine neurotransmission. The second most significant peak was on chr X: 86.6-86.8 Mb (P = 1.7 9 10 -5 ), near Pit2 (plasmacytoma expressed transcript 2) which is expressed in substantia nigra (Lagrue et al. 2010 ), a region thought to be affected in TD (Chen et al. 2011 ). The third most significant peak occurred on chr 9: 91.8-92.0 Mb (P = 3.0 9 10 -5 ), flanking two genes also expressed in brain motor control regions: Zic4 (zinc finger protein of the cerebellum 4) and Plscr1 (phospholipid scramblase 1). Finally, the fourth most significant peak (chr 13: 53.912-53.914 Mb, P = 4.6 9 10 -5 ) was adjacent to the dopamine receptor gene Drd1a, of great interest since haloperidol binds this receptor (Hsin-tung and Simpson 2000) and downregulates it in prefrontal cortex (Lidow and Goldman-Rakic 1994) . As with all of the Orofacial associations, this chr 13 locus was seen with all four analytical methods ( Table 1 ). The individual strain genotypes for the top SNPs listed in Table 1 are listed  in Supplementary Table 4. HAL30 (Fig. 2b) had loci on chr 6: 50.92-51.02 Mb (P = 1.1 9 10 -5 ) and chr 15: 23.54-25.64 (P = 1.4 9 10 -5 ) that narrowly missed reaching genome-wide significance. Both of these peaks occurred in regions harboring genes of primarily unknown function. Three other suggestive peaks were seen, two on chr 17 and one on chr 19. The chr 19 peak occurs within a liver-expressed anion exchanger, Slc26a8.
EPS (Fig. 2c ) also had associations that narrowly missed permutation-based genome-wide significance, including four peaks of similar magnitude on chrs 2, 3, 11, and 12. The significance threshold for EPS (8.7 9 10 -13 ) was higher because this phenotype was essentially dichotomous: 4 of 27 strains showed high levels of rigidity and three of these are derived from New Zealand.
OFA (Fig. 2d) showed several peaks of similar height that failed to reach the significance threshold. Two well-known neurodevelopmental genes Ncam2 (neuronal cell adhesion molecule 2) and Plxna2 (plexin A2), were within these regions.
Pathway analysis
Since we analyzed complex genetic traits and our sample size was relatively small, clear-cut identification of genome- Fig. 2 Genome-wide association results from EMMA for a orofacial, b HAL30, c EPS, and d OFA. Chromosome position is on the x axis and the -log P value is on the y axis. The dashed horizontal line indicates the permutation-based genome-wide significance level, which is unique for each phenotype wide significant loci was perhaps unlikely. Some proportion of the top loci could contain true signals that did not reach genome-wide significance due to low power. Therefore, we ran pathway analysis on the top 1% of genes in each phenotype. Table 2 and Supplementary Figs. 5-8 describe these networks. Many of these networks have biological plausibility, and some genes in these networks have known roles in movement disorders, neurotransmission, and drug absorption, distribution, metabolism, and excretion (ADME). For example, the Orofacial networks contained the primary receptor for haloperidol (dopamine receptor D2, Drd2), two glutamate receptors (Grin1 and Grin2a), the Huntington's disease gene (Htt), and Ncam1, as mentioned above.
For HAL30, only one network was significantly associated with the phenotype and it acts in liver development and function. Data from humans indicate that about 40% of haloperidol is subject to reabsorption via enterohepatic recycling (Eddington and Young 1990; Froemming et al. 1989) . Therefore, it is intriguing that at least one gene in this network, Abcc3 (multidrug resistance protein 3), is known to regulate biliary secretion. Slc4a4, also in this pathway, modulates renal tubular pH which is a critical factor in drug elimination via urine. EPS was also associated with a liver network, including the ADME-related genes Cyp17a1, Slco1a2, and Abcc3. The second network contained genes that are mutated in human neurological diseases: Grik1 (epilepsy), Wnt3a (neural tube defects), Mtmr7 (myotubular myopathy). The top network for OFA listed a number of genes that when knocked out in mice, result in abnormal behavior, including activity differences. These included the glutamate receptors Grik2, Grin1, and Grin2a, and the calcium/calmodulin-dependent protein kinase Camk2b (Mohn et al. 1999; Sakimura et al. 1995; Shaltiel et al. 2008; van Woerden et al. 2009 ). Table 3 highlights published mouse QTLs that are within 5 Mb of an EMMA SNP with P B 0.0001; a 5-Mb window was used since most of these eQTLs were mapped using low-resolution crosses (F 2 or BXD). It is intriguing that all three pharmacodynamic phenotypes (Orofacial, EPS, OFA) share confidence intervals with at least five QTLs for compounds that act directly (haloperidol, cocaine, and methamphetamine) or indirectly (ethanol) on dopaminergic neurotransmission.
Bioinformatic analysis
We used the Sanger SNPs database to determine the functional consequence of each EMMA SNP with P B 0.0001. Furthermore, since the Sanger database has full-genome sequence for 13 of our 27 strains, we were also able to identify genomic regions where the strain distribution pattern matched our top EMMA SNPs (restricted to ±40 kb from the EMMA SNP). In this way, we identified hundreds of additional variants linked to the genotyped SNP markers, including several putatively functional variants (see Table 4 ). With Orofacial, for example, we found that a VCM-protective haplotype on chr 5 is linked to a SNP in the 3 0 UTR of Nkx6-1, a gene that plays an essential role in midbrain dopaminergic neuron development (Prakash and Wurst 2006) . In addition, we found that the strain with the highest level of haloperidol-induced VCMs (DBA/2 J) has two variants within the 5 0 UTR of striatum-expressed Plscr1 and a nonsynonymous coding SNP within the predicted gene EG624120.
CNV analysis
CNVs are another form of genetic variation that could explain the heritability of these traits. We performed GWA with a set of 4,047 structural variants predicted to occur from Mouse Diversity Array data from these strains. Supplementary Table 5 lists the five most significant CNVs for each phenotype after GWA and the corresponding genes with at least one exon lost or gained due to deletion or duplication. For Orofacial, we found a strong relationship between duplication of Mtch2 (mitochondrial carrier homolog 2) and increased haloperidol-induced VCMs. The five strains with this duplication all fall within the top 9 strains in a 27-strain ranking of the Orofacial variable. Duplication of Mtch2 is a plausible variant for contributing to VCM susceptibility, given its role in apoptosis (Zaltsman et al. 2010 ) and the possible role of neurolepticinduced neuronal toxicity (via apoptosis) in TD (Galili et al. 2000; Mitchell et al. 2002; Skoblenick et al. 2006) . With OFA, a deletion of Epha6 was found in the two strains with the greatest haloperidol-induced decrease in activity (NZL and NZW), and EPHA6 was associated with therapeutic response to the neuroleptic risperidone (Ikeda et al. 2010) . Furthermore, its expression was significantly increased in mouse frontal cortex following chronic risperidone treatment (Ikeda et al. 2010) .
Next, since SNPs are capable of tagging CNVs, we looked for overlap between CNVs and the top 1% of SNPassociated loci for each phenotype (Supplementary Table 6 ). A total of six variants, all deletions, were found in the vicinity of the top SNPs, though only one of them resulted in loss of exons. For Orofacial, a deletion on chr 9 in the SM/J strain (which showed average VCM susceptibility) was found to flank two genes mentioned above with expression in brain motor control regions: Zic4 and Plscr1.
Gene expression analysis
Gene expression data can be used to prioritize regions for follow-up (Aylor et al. 2011) . Therefore, we sought to determine if brain gene expression correlated with any of . Genes in parentheses are the upstream and downstream nearest genes to the locus: (upstream, downstream) . Genes in bold are mentioned in the results the phenotypes examined or with SNPs within EMMAsignificant loci. We collected whole-brain tissue from mice that had been chronically treated with haloperidol for 120 days [the same mice used in Crowley et al. (2010) ]. Whole-brain tissue was used because the pathophysiology of EPS is thought to include several dispersed neuroanatomical regions (Koshikawa et al. 2011 ) and we found it more desirable to capture all regions rather than microdissect a single region. Since the Crowley et al. study did not have a placebo-treated arm (but rather focused on differences before and after drug treatment), we did not have tissue from untreated animals to use as a comparison group. We deemed it a worthwhile experiment, however, since if haloperidol susceptibility was tightly linked to the expression level of a particular transcript (or a set of transcripts in a biological pathway) after haloperidol treatment, it should be detectable. We prioritized transcripts near: (1) top EMMA SNPs that correlated with gene expression in cis, (2) the top 1% of genes in terms of correlation between expression and phenotype, and (3) expression levels for the most interesting candidate genes derived from the SNP GWAS, CNV GWAS, and pathway analysis. First, we collected all probe sets within 1 Mb of EMMA SNPs with P \ 0.0001, stratified gene expression values by SNP genotype, and tested for a significant expression difference between the two genotypes. For each phenotype, a large number of genes showed evidence of cis regulation (see Supplementary Table 7) . For example, with Orofacial we tested 287 probe sets and 61 were consistent with cisregulation at a false discovery rate of 5%. Among these genes were the dopamine receptor Drd1a, liver enzyme 1E-14 11 Cancer, genetic disorder, reproductive system disease 2 Acat1, Adam10, Akap9, Arc, Bcar1, Cam2 kb, Cdh2, Cltc, Dclk1, Dlg2, Dlg3, Dlg4, Dlgap1, Dlgap3, Drd2, Fyn, Grik2, Grin1, Grin2a, Hspa1a, Mpl, Ncam1, Nsf, Ntrk2, Penk, Pgk1, Plat, Prkaca, Rims1, Scn2a, Slc25a4, Sp1, Syngap1
1E-11 9 Nervous system development and function, cell-to-cell signaling and interaction, behavior
1E-30 18
Hematological system development and function, cell morphology, growth and proliferation
1E-16 11 Hepatic system disease, liver cholestasis, lipid metabolism Cyp46a1, the cerebellar gene Zic4 mentioned above, and also a related gene, Zic1. The other three phenotypes showed fewer immediately obvious candidates. Second, we examined the relationship between gene expression of the top 1% of associated genes (Supplementary Table 8 ) and phenotype. For Orofacial, this list included two synthetic enzymes and one receptor binding partner for the primary inhibitory neurotransmitter in the brain, GABA (Gad1, Gad2, and Gabarapl2). HAL30 associated with several metabolic genes (e.g., Cyp2a22), EPS correlated with several neurotransmitter-related genes, including the dopamine-transporting vesicular monoamine transporter 1 (Slc18a1), and OFA associated with a number of genes that show brain expression, though of less obvious relevance to haloperidol.
Finally, we have identified many intriguing quantitative trait gene candidates through SNP GWAS, CNV GWAS, and pathway analysis. Supplementary Table 9 Tables 1 and 2 and Supplementary  Table 5) . We searched for genes whose expression levels are among the top 20% of genes in terms of association with the phenotype. First, two direct targets of haloperidol (Drd1 and Drd2) tend to correlate with Orofacial. Six other genes identified by genetic analysis were similarly linked to Orofacial, including the glutamate receptor gene Grin1. The HAL30 results are more difficult to interpret for the reasons mentioned above, though the renal transporter Slc4a4 fell within the top 20%. There was an interesting set of genes that we initially found with Orofacial but whose expression was correlated more with EPS (Cpeb2, Pet2, Ncam1, and Plscr1). This suggests the possibility of pleiotropic effects for these genes, regulating susceptibility for two distinct haloperidol ADRs. Finally, OFA had three candidate genes in the top 20%, including the risperidone-responsive gene Epha6.
lists association
Discussion
The purpose of this report was to investigate the genetics of several haloperidol-associated phenotypes with the eventual goal of improving understanding of the genomics of human TD. If VCMs are a reasonable analog of TD, then it might be possible to accelerate discovery by using a design whereby mouse genetic mapping resources are used to screen the genomic search space to derive high-probability targets whose orthologs can be studied in human samples. In this way, the multiple-testing burden is paid in a relatively inexpensive and experimentally tractable system and human samples are used only for testing candidate targets. To achieve this end, we selected optimal phenotypes from Crowley et al. (2010) and took a comprehensive genomic analysis approach. First, we mapped QTLs for haloperidol response using 27 inbred strains and 426,493 SNPs. This approach led to QTLs of much higher resolution than with traditional mouse mapping methods, which have employed populations with lower diversity (i.e., F 2 cross or BXD recombinant inbred lines) and lower-density genotyping (*500 markers). For example, our largest locus spans just 2.1 Mb (HAL30 association on chr 15), while the confidence intervals from traditional mouse QTL studies can easily cover 20 Mb and include hundreds of genes. Our top peaks pointed to a number of interesting genes, only one of which has ever been included in a TD candidate gene study (Drd1). For our three pharmacodynamic traits, we identified genes expressed in the striatum (Plscr1, Bche, and Drd1), neurodevelopmental regulators (Ncam2 and Plxna2), a key cerebellum gene (Zic4), and *20 genes of currently unknown function.
Second, we performed pathway analysis using our top GWA loci. The top networks for each phenotype were consistent with the phenotypes, suggesting that our top loci contained true signal, but did not reach genome-wide significance due to low power. Also consistent with this idea is the presence of haloperidol's primary receptor (Drd2) within the second Orofacial network. As mentioned in the Results section, pathway analysis revealed a number of additional genes that are plausible candidates for TD/EPS, including three glutamate receptors (Grik2, Grin1, and Grin2a) and genes known to cause neurological disease (Grik1, Wnt3a, and Mtmr7). As for haloperidol plasma levels, our overall pattern of results seems to suggest a role for enterohepatic recycling, perhaps via Abcc3 (multidrug resistance protein 3).
Third, we collected a wealth of bioinformatic data on the top peaks of interest. When we looked at the published mouse QTLs surrounding our top SNPs, it was reassuring to find how many of these were related to dopaminergic drug response. All three of our pharmacodynamic phenotypes shared confidence intervals with at least five QTLs for compounds that act on dopamine (haloperidol, cocaine, methamphetamine, and ethanol), while HAL30 shared no QTLs with these compounds. This congruence is encouraging, but the ultimate goal of QTL studies is to identify the causal quantitative trait nucleotide (QTN) underlying the QTL (Mackay et al. 2009 ). Identification of the QTN has been the rate-limiting step in traditional mouse complex trait studies, owing in part to a lack of polymorphism data genome-wide. However, increasing amounts of genomic data in mice make this task straightforward to search for variants with a strain distribution pattern consistent with causality. We used the Sanger database to identify hundreds of additional variants linked to the genotyped SNP markers, including several putatively functional variants. Of particular interest was a VCM-protective haplotype on chr 5 linked to a SNP in the 3 0 UTR of Nkx6-1, a gene required for midbrain dopaminergic neuron development (Prakash and Wurst 2006) . It is conceivable that altered dopaminergic function via polymorphism in Nkx6-1 could predispose mice to haloperidol-induced adverse drug reactions.
Fourth, we tested whether CNVs affected these traits. We performed GWA with a set of 4,047 structural variants known to occur in these strains and also looked for overlap between CNVs and the top 1% of SNP-associated loci. In the CNV GWA, we found a strong relationship between duplication of the Mtch2 (mitochondrial carrier homolog 2) gene and increased haloperidol-induced VCMs. This is interesting given the role of Mtch2 in apoptosis and the literature implicating neuroleptic-induced neuronal toxicity (via apoptosis) in the development of TD (Galili et al. 2000; Mitchell et al. 2002; Skoblenick et al. 2006 ). In addition, the relationship between a deletion of Epha6 and haloperidol-induced decreased activity is intriguing given the results of a recent clinical study linking this gene to risperidone treatment response (Ikeda et al. 2010 ). Finally, it was notable that the liver-expressed gene Supt3 h was deleted in two strains with high plasma drug levels.
Finally, we examined the relationship between our findings and brain gene expression following withdrawal from chronic haloperidol treatment. This extra step provided a plausible method for prioritizing candidate genes within our top loci for follow-up. For example, since Drd1a is located within one of our top Orofacial loci and is cis-regulated, it is reasonable to hypothesize that gene regulatory variation in this gene could underlie the QTL.
In conclusion, we have identified *50 genes that we expect to have high prior probabilities for association with haloperidol-induced TD. Furthermore, since the human genome contains *25,000 genes, we have provided a logical rationale for focusing on just a small fraction (0.2%) of that genomic search space. As such, the multipletesting penalty is reduced 500-fold.
